Telomerase and mitochondria inhibition promote apoptosis and TET2 and ANMT3a expression in triple negative breast cancer cell lines

被引:1
作者
Mazloumi, Zeinab [1 ,2 ]
Rafat, Ali [3 ]
Asl, Khadijeh Dizaji [4 ]
Karimipour, Mohammad [5 ]
Shanehbandi, Dariush [6 ]
Talebi, Mehdi [1 ]
Montazer, Majid [7 ]
Movassaghpour, Ali Akbar [8 ]
Dehnad, Alireza [9 ]
Farahzadi, Raheleh [8 ]
Charoudeh, Hojjatollah Nozad [8 ]
机构
[1] Tabriz Univ Med Sci, Fac Adv Med Sci, Dept Appl Cell Sci, Tabriz, Iran
[2] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran
[3] Kashan Univ Med Sci, Inst Basic Sci, Anat Sci Res Ctr, Kashan, Iran
[4] Islamic Azad Univ, Fac Med Sci, Dept Histopathol & Anat, Tabriz Med Sci, Tabriz, Iran
[5] Tabriz Univ Med Sci, Dept Anat Sci, Tabriz, Iran
[6] Tabriz Univ Med Sci, Fac Med, Immunol Res Ctr, Tabriz, Iran
[7] Tabriz Univ Med Sci, Imam Reza Hosp, Dept Cardiovasc Surg, Tabriz, Iran
[8] Tabriz Univ Med Sci, Stem Cell Res Ctr, Tabriz, Iran
[9] AREEO, Razi Vaccine & Serum Res Inst, Dept Bacterial Dis Res, Tabriz, Iran
关键词
Cancer stem cell; Telomerase; Mitochondria; Apoptosis; DNMT3a; TET2; Triple negative breast cancer; TRAIL-INDUCED APOPTOSIS; LEUKEMIA; HTERT; INTERFERENCE; TARGET; BCL-2;
D O I
10.34172/bi.2023.27640
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: High metastasis, resistance to common treatments, and high mortality rate, has made triple -negative breast cancer (TNBC) to be the most invasive type of breast cancer. High telomerase activity and mitochondrial biogenesis are involved in breast cancer tumorigenesis. The catalytic subunit of telomerase, telomerase reverse transcriptase (hTERT), plays a role in telomere lengthening and extra -biological functions such as gene expression, mitochondria function, and apoptosis. In this study, it has been aimed to evaluate intrinsic-, extrinsic-apoptosis and DNMT3a and TET2 expression following the inhibition of telomerase and mitochondria respiration in TNBC cell lines. Methods: TNBC cells were treated with IC50 levels of BIBR1532, tigecycline, and also their combination. Then, telomere length, and DNMT3a, TET2, and hTERT expression were evaluated. Finally, apoptosis rate, apoptosis-related proteins, and genes were analyzed. Results: The present results showed that IC50 level of telomerase and inhibition of mitochondria respiration induced apoptosis but did not leave any significant effect on telomere length. The results also indicated that telomerase inhibition induced extrinsic-apoptosis in MDA-MB-231 and caused intrinsic- apoptosis in MDA-MB-468 cells. Furthermore, it was found that the expression of p53 decreased and was ineffective in cell apoptosis. The expressions of DNMT3a and TET2 increased in cells. In addition, combination treatment was better than BIBR1532 and tigecycline alone. Conclusion: The inhibition of telomerase and mitochondria respiration caused intrinsic- and extrinsic- apoptosis and increased DNMT3a and TET2 expression and it could be utilized in breast cancer treatment.
引用
收藏
页数:10
相关论文
共 59 条
  • [1] The Small Molecule BIBR1532 Exerts Potential Anti-cancer Activities in Preclinical Models of Feline Oral Squamous Cell Carcinoma Through Inhibition of Telomerase Activity and Down-Regulation of TERT
    Altamura, Gennaro
    degli Uberti, Barbara
    Galiero, Giorgio
    De Luca, Giovanna
    Power, Karen
    Licenziato, Luca
    Maiolino, Paola
    Borzacchiello, Giuseppe
    [J]. FRONTIERS IN VETERINARY SCIENCE, 2021, 7
  • [2] Arora R., 2018, STEM FELLOWSH J, V4, P5, DOI [10.17975/sfj-2018-002, DOI 10.17975/SFJ-2018-002]
  • [3] Effects of telomerase inhibitor on epigenetic chromatin modification enzymes in malignancies
    Avci, Cigir Biray
    Dogan, Fatma
    Ay, Neslihan Pinar Ozates
    Bagca, Bakiye Goker
    Abbaszadeh, Zeka
    Gunduz, Cumhur
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2018, 119 (12) : 9817 - 9824
  • [4] Survival signaling goes BAD
    Bergmann, A
    [J]. DEVELOPMENTAL CELL, 2002, 3 (05) : 607 - 608
  • [5] Key Immune Cell Cytokines Affects the Telomere Activity of Cord Blood Cells In vitro
    Brazvan, Balal
    Farahzadi, Raheleh
    Mohammadi, Seyede Momeneh
    Saheb, Soheila Montazer
    Shanehbandi, Dariush
    Schmied, Laurent
    Rad, Jafar Soleimani
    Darabi, Masoud
    Charoudeh, Hojjatollah Nozad
    [J]. ADVANCED PHARMACEUTICAL BULLETIN, 2016, 6 (02) : 153 - 161
  • [6] Specific functions of TET1 and TET2 in regulating mesenchymal cell lineage determination
    Cakouros, Dimitrios
    Hemming, Sarah
    Gronthos, Kahlia
    Liu, Renjing
    Zannettino, Andrew
    Shi, Songtao
    Gronthos, Stan
    [J]. EPIGENETICS & CHROMATIN, 2019, 12 (1)
  • [7] Short-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells
    Celeghin, Andrea
    Giunco, Silvia
    Freguja, Riccardo
    Zangrossi, Manuela
    Nalio, Silvia
    Dolcetti, Riccardo
    De Rossi, Anita
    [J]. CELL DEATH & DISEASE, 2016, 7 : e2562 - e2562
  • [8] Ruthenium complexes boost NK cell immunotherapy via sensitizing triple-negative breast cancer and shaping immuno-microenvironment
    Chen, Qi
    He, Lizhen
    Li, Xiaoying
    Xu, Ligeng
    Chen, Tianfeng
    [J]. BIOMATERIALS, 2022, 281
  • [9] TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics
    Chou, Wen-Chien
    Chou, Sheng-Chieh
    Liu, Chieh-Yu
    Chen, Chien-Yuan
    Hou, Hsin-An
    Kuo, Yuan-Yeh
    Lee, Ming-Cheng
    Ko, Bor-Sheng
    Tang, Jih-Luh
    Yao, Ming
    Tsay, Woei
    Wu, Shang-Ju
    Huang, Shang-Yi
    Hsu, Szu-Chun
    Chen, Yao-Chang
    Chang, Yi-Chang
    Kuo, Yi-Yi
    Kuo, Kuan-Ting
    Lee, Fen-Yu
    Liu, Ming-Chi
    Liu, Chia-Wen
    Tseng, Mei-Hsuan
    Huang, Chi-Fei
    Tien, Hwei-Fang
    [J]. BLOOD, 2011, 118 (14) : 3803 - 3810
  • [10] Digital Analysis of BCL2 Expression in Laryngeal Squamous Cell Carcinoma
    Chrysovergis, Aristeidis
    Papanikolaou, Vasileios S.
    Tsiambas, Evangelos
    Ragos, Vasileios
    Peschos, Dimitrios
    Kyrodimos, Efthymios
    [J]. ANTICANCER RESEARCH, 2019, 39 (03) : 1253 - 1257